266 related articles for article (PubMed ID: 30135206)
21. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced
Wu B; Song M; Dong Q; Xiang G; Li J; Ma X; Wei F
Theranostics; 2022; 12(11):5086-5102. PubMed ID: 35836797
[No Abstract] [Full Text] [Related]
22. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.
Bouillez A; Rajabi H; Jin C; Samur M; Tagde A; Alam M; Hiraki M; Maeda T; Hu X; Adeegbe D; Kharbanda S; Wong KK; Kufe D
Oncogene; 2017 Jul; 36(28):4037-4046. PubMed ID: 28288138
[TBL] [Abstract][Full Text] [Related]
23. Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression.
Balan M; Mier y Teran E; Waaga-Gasser AM; Gasser M; Choueiri TK; Freeman G; Pal S
J Biol Chem; 2015 Mar; 290(13):8110-20. PubMed ID: 25645920
[TBL] [Abstract][Full Text] [Related]
24. Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours.
Martin V; Chiriaco C; Modica C; Acquadro A; Cortese M; Galimi F; Perera T; Gammaitoni L; Aglietta M; Comoglio PM; Vigna E; Sangiolo D
Br J Cancer; 2019 Mar; 120(5):527-536. PubMed ID: 30723303
[TBL] [Abstract][Full Text] [Related]
25. p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.
Liu J; He D; Cheng L; Huang C; Zhang Y; Rao X; Kong Y; Li C; Zhang Z; Liu J; Jones K; Napier D; Lee EY; Wang C; Liu X
Oncogene; 2020 May; 39(19):3939-3951. PubMed ID: 32203167
[TBL] [Abstract][Full Text] [Related]
26. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
Gao Y; Yang J; Cai Y; Fu S; Zhang N; Fu X; Li L
Int J Cancer; 2018 Aug; 143(4):931-943. PubMed ID: 29516506
[TBL] [Abstract][Full Text] [Related]
27. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
Thiem A; Hesbacher S; Kneitz H; di Primio T; Heppt MV; Hermanns HM; Goebeler M; Meierjohann S; Houben R; Schrama D
J Exp Clin Cancer Res; 2019 Sep; 38(1):397. PubMed ID: 31506076
[TBL] [Abstract][Full Text] [Related]
28. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.
Cerezo M; Guemiri R; Druillennec S; Girault I; Malka-Mahieu H; Shen S; Allard D; Martineau S; Welsch C; Agoussi S; Estrada C; Adam J; Libenciuc C; Routier E; Roy S; Désaubry L; Eggermont AM; Sonenberg N; Scoazec JY; Eychène A; Vagner S; Robert C
Nat Med; 2018 Dec; 24(12):1877-1886. PubMed ID: 30374200
[TBL] [Abstract][Full Text] [Related]
29. The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation.
Shang M; Yang H; Yang R; Chen T; Fu Y; Li Y; Fang X; Zhang K; Zhang J; Li H; Cao X; Gu J; Xiao J; Zhang Q; Liu X; Yu Q; Wang T
Nat Commun; 2021 Mar; 12(1):1940. PubMed ID: 33782411
[TBL] [Abstract][Full Text] [Related]
30. Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.
Coelho MA; de Carné Trécesson S; Rana S; Zecchin D; Moore C; Molina-Arcas M; East P; Spencer-Dene B; Nye E; Barnouin K; Snijders AP; Lai WS; Blackshear PJ; Downward J
Immunity; 2017 Dec; 47(6):1083-1099.e6. PubMed ID: 29246442
[TBL] [Abstract][Full Text] [Related]
31. Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1.
He B; Yan F; Wu C
Biomed Pharmacother; 2018 Feb; 98():95-101. PubMed ID: 29247952
[TBL] [Abstract][Full Text] [Related]
32. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
33. Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS.
Yoyen-Ermis D; Tunali G; Tavukcuoglu E; Horzum U; Ozkazanc D; Sutlu T; Buyukasik Y; Esendagli G
Sci Rep; 2019 Aug; 9(1):11697. PubMed ID: 31406210
[TBL] [Abstract][Full Text] [Related]
34. Regulation of PD-L1 Expression by NF-κB in Cancer.
Antonangeli F; Natalini A; Garassino MC; Sica A; Santoni A; Di Rosa F
Front Immunol; 2020; 11():584626. PubMed ID: 33324403
[TBL] [Abstract][Full Text] [Related]
35. PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling.
Gao H; Zhang J; Ren X
Biosci Rep; 2019 Dec; 39(12):. PubMed ID: 31799599
[TBL] [Abstract][Full Text] [Related]
36. BCL3 Reduces the Sterile Inflammatory Response in Pancreatic and Biliary Tissues.
Song L; Wörmann S; Ai J; Neuhöfer P; Lesina M; Diakopoulos KN; Ruess D; Treiber M; Witt H; Bassermann F; Halangk W; Steiner JM; Esposito I; Rosendahl J; Schmid RM; Riemann M; Algül H
Gastroenterology; 2016 Feb; 150(2):499-512.e20. PubMed ID: 26526716
[TBL] [Abstract][Full Text] [Related]
37. CD137 ligand feedback upregulates PD-L1 expression on lung cancer via T cell production of IFN-γ.
Wang H; Yan Z; Hao J; Yang B; Wang J; Yi L; Wang X; Li S; Zhang H; Zhang S
Thorac Cancer; 2019 Dec; 10(12):2225-2235. PubMed ID: 31625289
[TBL] [Abstract][Full Text] [Related]
38. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
[TBL] [Abstract][Full Text] [Related]
39. IL-12 regulates B7-H1 expression in ovarian cancer-associated macrophages by effects on NF-κB signalling.
Xiong HY; Ma TT; Wu BT; Lin Y; Tu ZG
Asian Pac J Cancer Prev; 2014; 15(14):5767-72. PubMed ID: 25081699
[TBL] [Abstract][Full Text] [Related]
40. IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma.
Moon JW; Kong SK; Kim BS; Kim HJ; Lim H; Noh K; Kim Y; Choi JW; Lee JH; Kim YS
Sci Rep; 2017 Dec; 7(1):17810. PubMed ID: 29259270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
